Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome : Episode 7
Data from the TELEPATH Trial and Real-World Analyses
Dr Pommier discusses key safety, efficacy, and quality of life data from the TELEPATH trial investigating the tryptophan hydroxylase inhibitor telotristat ethyl, while Dr Das comments on real-world data complements to the trial.
EP: 1.Overview of Neuroendocrine Tumors (NETs)
EP: 2.Overview of Carcinoid Syndrome (CS)
EP: 3.Overview of Carcinoid Heart Disease (CHD)
EP: 4.Management of Carcinoid Syndrome-Related Symptoms
EP: 5.Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome
EP: 6.Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome
Now Viewing
EP: 7.Data from the TELEPATH Trial and Real-World Analyses
EP: 8.Prevention, Treatment, and Management of Carcinoid Heart Disease
EP: 9.Unmet Needs for Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
EP: 10.Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome
Related Videos
Related Content
